An interventional study of total knee arthroplasty in Avascular Necrosis, Post-traumatic; Arthrosis and Knee Osteoarthritis, sponsored by Zimmer, GmbH. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-13.
Sponsored by Zimmer, GmbH · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Osteonecrosis by Zimmer Biomet — 3 open to participants now, 15 under way, none of them phase 3. Osteonecrosis · Zimmer Biomet.
Among the 57 studies in Osteonecrosis by Zimmer Biomet, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2014, is one of 15 with no phase, and was the 32nd registered.
287 studies on the registry are indexed under Osteonecrosis; 46 are open to participants now.
Browse Osteonecrosis studies →3 of the 57 studies in Osteonecrosis by Zimmer Biomet are open now, in 4 countries. Recruiting first, the newest first:
Paragon 28 · Sites in United States
Ages 21+
Zimmer Biomet · Sites in United States
Ages 18–80
Zimmer Biomet · Sites in United States, Belgium, Italy and 1 more country
Ages 18–80
By country, each count listing its studies:
Of the 23 Osteonecrosis studies recruiting now, 14 (61%) set no upper age limit and 4 (17%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2014.
This study's enrollment of 72 is close to the median of 67 across 152 interventional studies indexed under Osteonecrosis.
Median enrollment 193 across the 16 interventional studies, 118 across the 41 observational. Of the 39 that completed or were terminated, 18 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Zimmer, GmbH, one of the names counted as Zimmer Biomet. Under that name alone:
Zimmer, GmbH is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
3 of the studies in Osteonecrosis by Zimmer Biomet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03409718Zimmer BiometDatabase Retrieval for the Comprehensive Shoulder | 2026-12 |
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT03372278Zimmer BiometPMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | 2027-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies in Osteonecrosis by Zimmer Biomet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this prospective study is to evaluate Zimmer® iASSIST™ with respect to radiographic, clinical and economic outcomes and compared to conventional instrumentation in primary total knee arthroplasty (NexGen or Persona knee implants).
The study design is a prospective, multicenter, comparative outcome study. The study requires each site to obtain IRB (Institutional Review Board) approval prior to study enrollment. All potential study subjects will be required to participate in the Informed Consent Process.
All study subjects will undergo preoperative clinical evaluations prior to their total knee arthroplasty. Investigators will collect clinical data for 12 months. Follow-up clinical visits include 3 and 12 months post-operatively.
The primary endpoint of this study is defined as component alignment as determined using long leg X-Rays. The secondary endpoint will be to evaluate the Knee Society Score, EQ-5D (EuroQol-5Dimensions) scoring system, operating room time, blood loss and complications
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient is able to:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients will have primary total knee arthroplasty with the iAssist. The iAssist Knee System is a computer assisted stereotaxic surgical instrument system to assist the surgeon in the positioning of orthopedic implant system components intra-operatively. It involves surgical instruments and position sensors to determine alignment axes in relation to anatomical landmarks and to precisely position alignment instruments and implant components relative to these axes.
Procedure: total knee arthroplasty
patients will have primary total knee arthroplasty with the conventional instrumentation.
Procedure: total knee arthroplasty
surgical procedure in which damaged parts of the knee joint are replaced with an implant.
Component Alignment
Assess the differences in component alignment, measured by the mean of radiographs, between iASSIST™ and conventional instrumentation in primary total knee arthroplasty (TKA) procedures.
Time frame: 1 year
Knee Society Score Assessment
Assess the differences in Knee Society Score between iASSIST™ and conventional instrumentation in primary TKA procedures. Higher (and better) score value: 100, lower value: 0. Score 80-100 = Excellent Score 70-79 = Good Score 60-69 = Fair Score below 60 = Poor
Time frame: 1 year
Knee Society Score Function
Knee Society Score function asses 12 months postoperatively between iASSIST™ and conventional instrumentation in primary TKA procedures. Higher (and better) score value: 100, lower value: 0. Score 80-100 = Excellent Score 70-79 = Good Score 60-69 = Fair Score below 60 = Poor
Time frame: 1 year
EQ-5D Questionnaire
Assess the differences in EQ-5D between iASSIST™ and conventional instrumentation in primary TKA procedures at 12 months postoperatively. Comparison of the derived EQ-5D scale and health state between the 2 groups. The EQ-5D questionnaire includes five dimensions (5D): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. EQ-5D values range from -0.2 to 1 where the negative values correspond to bad health states (states worse than death), and 1.0 corresponds to perfect health.
Time frame: 1 year
| Milestone | iAssist Group | Conventional Instrumentation Group |
|---|---|---|
| Started | 45 | 27 |
| Completed | 44 | 26 |
| Not completed | 1 | 1 |
Assess the differences in component alignment, measured by the mean of radiographs, between iASSIST™ and conventional instrumentation in primary total knee arthroplasty (TKA) procedures.
| degree | iAssist Group | Conventional Instrumentation Group |
|---|---|---|
| Component Alignment | 179 ± 2.9 | 178 ± 3.9 |
Assess the differences in Knee Society Score between iASSIST™ and conventional instrumentation in primary TKA procedures. Higher (and better) score value: 100, lower value: 0. Score 80-100 = Excellent Score 70-79 = Good Score 60-69 = Fair Score below 60 = Poor
| score on a scale | iAssist Group | Conventional Instrumentation Group |
|---|---|---|
| Knee Society Score Assessment | 74.7 ± 12.5 | 72.4 ± 11.6 |
Knee Society Score function asses 12 months postoperatively between iASSIST™ and conventional instrumentation in primary TKA procedures. Higher (and better) score value: 100, lower value: 0. Score 80-100 = Excellent Score 70-79 = Good Score 60-69 = Fair Score below 60 = Poor
| score on a scale | iAssist Group | Conventional Instrumentation Group |
|---|---|---|
| Knee Society Score Function | 80.5 ± 13.8 | 78.5 ± 19.1 |
Assess the differences in EQ-5D between iASSIST™ and conventional instrumentation in primary TKA procedures at 12 months postoperatively. Comparison of the derived EQ-5D scale and health state between the 2 groups. The EQ-5D questionnaire includes five dimensions (5D): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. EQ-5D values range from -0.2 to 1 where the negative values correspond to bad health states (states worse than death), and 1.0 corresponds to perfect health.
| score on a scale | iAssist Group | Conventional Instrumentation Group |
|---|---|---|
| EQ-5D Questionnaire | 0.8 ± 0.2 | 0.8 ± 0.3 |
Collected over The adverse events were collected preoperatively, intraoperatively and postoperatively (at 3 months ±2 weeks and 12 months ±1 month postoperative).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| iAssist Group | 0/45 (0%) | 2/45 (4.4%) | 7/45 (15.6%) |
| Conventional Instrumentation Group | 0/27 (0%) | 4/27 (14.8%) | 3/27 (11.1%) |
| Event | iAssist Group | Conventional Instrumentation Group |
|---|---|---|
| Implant failureSurgical and medical procedures | 0/45 | 1/27 |
| Pulmonary embolismVascular disorders | 0/45 | 1/27 |
| Lump in the neck: metastasis,as well as in the lungsGeneral disorders | 0/45 | 1/27 |
| Patella transverse fracture+dislocation of the prosthesis+tibia shaft fracture+infeSurgical and medical procedures | 0/45 | 1/27 |
| Poor alignment in tibia componentSurgical and medical procedures | 1/45 | 0/27 |
| Sepsis in bronchial asthma, infection exacerbationInfections and infestations | 1/45 | 0/27 |
| Event | iAssist Group | Conventional Instrumentation Group |
|---|---|---|
| Flexion ContractureGeneral disorders | 1/45 | 1/27 |
| Pain in the calf (deep vein thrombosis)Vascular disorders | 0/45 | 1/27 |
| patient felt on the floor, he wanted to stand up aloneSocial circumstances | 0/45 | 1/27 |
| Patient still had a joint effusion 6 months after surgerySurgical and medical procedures | 0/45 | 1/27 |
| Allergic reaction after eating nutsGeneral disorders | 1/45 | 0/27 |
| Allergic reaction unclear cause (itching, dyspnea, rash)General disorders | 1/45 | 0/27 |
| Radius fractureSurgical and medical procedures | 1/45 | 0/27 |
| Allergic reaction (Dafalgan)General disorders | 1/45 | 0/27 |
| Foot fractureSurgical and medical procedures | 1/45 | 0/27 |
| Delayed Wound HealingSurgical and medical procedures | 1/45 | 0/27 |
| Age, Continuous(years) | iAssist Group | Conventional Instrumentation Group | Total |
|---|---|---|---|
| Mean | 67.3 ± 7.9 | 70.3 ± 7.4 | 68.4 ± 7.8 |
| Sex: Female, Male(Participants) | iAssist Group | Conventional Instrumentation Group | Total |
|---|---|---|---|
| Female | 30 | 17 | 47 |
| Male | 15 | 10 | 25 |
| Race and Ethnicity Not Collected(Participants) | iAssist Group | Conventional Instrumentation Group | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Weight kg(kg) | iAssist Group | Conventional Instrumentation Group | Total |
|---|---|---|---|
| Mean | 81.4 ± 17.2 | 84.3 ± 13.0 | 82.5 ± 15.7 |
| Body Mass Index (BMI) kg/m^2(kg/m^2) | iAssist Group | Conventional Instrumentation Group | Total |
|---|---|---|---|
| Mean | 30.4 ± 5.5 | 30.7 ± 4.6 | 30.5 ± 5.1 |
| Height cm(cm) | iAssist Group | Conventional Instrumentation Group | Total |
|---|---|---|---|
| Mean | 163.5 ± 10.6 | 166.0 ± 9.6 | 164.5 ± 10.3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2014 to primary completion in Dec 2018, 56 months.
Results were first posted in Apr 2021, 2 years 4 months after primary completion.
Of 45 interventional studies with no phase under Osteonecrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 91. This study's 56 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.